1
|
Mercier R, LaPointe P. The role of cellular proteostasis in anti-tumor immunity. J Biol Chem 2022; 298:101930. [PMID: 35421375 PMCID: PMC9108985 DOI: 10.1016/j.jbc.2022.101930] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 03/21/2022] [Accepted: 03/31/2022] [Indexed: 12/25/2022] Open
Abstract
Immune checkpoint blockade therapy is perhaps the most important development in cancer treatment in recent memory. It is based on decades of investigation into the biology of immune cells and the role of the immune system in controlling cancer growth. While the molecular circuitry that governs the immune system in general - and anti-tumor immunity in particular - is intensely studied, far less attention has been paid to the role of cellular stress in this process. Proteostasis, intimately linked to cell stress responses, refers to the dynamic regulation of the cellular proteome and is maintained through a complex network of systems that govern the synthesis, folding, and degradation of proteins in the cell. Disruption of these systems can result in the loss of protein function, altered protein function, the formation of toxic aggregates, or pathologies associated with cell stress. However, the importance of proteostasis extends beyond its role in maintaining proper protein function; proteostasis governs how tolerant cells may be to mutations in protein coding genes and the overall half-life of proteins. Such gene expression changes may be associated with human diseases including neurodegenerative diseases, metabolic disease, and cancer and manifest at the protein level against the backdrop of the proteostasis network in any given cellular environment. In this review, we focus on the role of proteostasis in regulating immune responses against cancer as well the role of proteostasis in determining immunogenicity of cancer cells.
Collapse
Affiliation(s)
- Rebecca Mercier
- Department of Cell Biology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Paul LaPointe
- Department of Cell Biology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
2
|
Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. Cancers (Basel) 2022; 14:cancers14051189. [PMID: 35267497 PMCID: PMC8909387 DOI: 10.3390/cancers14051189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/21/2022] [Accepted: 02/22/2022] [Indexed: 02/05/2023] Open
Abstract
Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability in high grade serous ovarian carcinoma (HGSOC) patients receiving primary debulking surgery followed by carboplatin-paclitaxel chemotherapy +/− nintedanib. Methods: 103 HGSOC patients’ tumor samples from phase III AGO-OVAR-12 were analyzed. A comprehensive analysis of the TME was performed by immunohistochemistry on tissue microarray. Comparative genomic hybridization was carried out to evaluate genomic instability signatures through homologous recombination deficiency (HRD) score, genomic index, and somatic copy number alterations. The relationship between genomic instability and TME was explored. Results: Patients with high intratumoral CD3+ T lymphocytes had longer progression-free survival (32 vs. 19.6 months, p = 0.009) and overall survival (OS) (median not reached). High HLA-E expression on tumor cells was associated with a longer OS (median OS not reached vs. 52.9 months, p = 0.002). HRD profile was associated with high HLA-E expression on tumor cells and an improved OS. In the multivariate analysis, residual tumor, intratumoral CD3, and HLA-E on tumor cells were more predictive than other parameters. Conclusions: Our results suggest HLA-E/CD94-NKG2A/2C is a potential immune target particularly in the HRD positive ovarian carcinoma subgroup.
Collapse
Affiliation(s)
- Jean-David Fumet
- GINECO & Department of Medical Oncology, Center GF Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France
- Platform of Transfer in Cancer Biology, 21079 Dijon, France;
- University of Bourgogne-Franche-Comté, 21000 Dijon, France
- Correspondence: (J.-D.F.); (N.B.-V.)
| | - Emilie Lardenois
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
| | - Isabelle Ray-Coquard
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- GINECO & Medical Oncology Department, Centre Léon Bérard, 28, rue Laennec, Université Claude Bernard Lyon 1, 69008 Lyon, France;
| | - Philipp Harter
- AGO & Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, 45136 Essen, Germany;
| | - Florence Joly
- GINECO & Department of Medical Oncology, Baclesse Cancer Center, 14118 Caen, France;
| | - Ulrich Canzler
- AGO & Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany & National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany;
| | - Caroline Truntzer
- Platform of Transfer in Cancer Biology, 21079 Dijon, France;
- Genetic and Immunology Medical Institute (GIMI), 21000 Dijon, France
- UMR INSERM 1231, 21000 Dijon, France
| | - Olivier Tredan
- GINECO & Medical Oncology Department, Centre Léon Bérard, 28, rue Laennec, Université Claude Bernard Lyon 1, 69008 Lyon, France;
| | - Clemens Liebrich
- AGO & Klinikum Wolfsburg, amO—Interdisziplinäres ambulantes Onkologiezentrum am Klieversberg, Sauerbruchstrasse 7, 38840 Wolfsburg, Germany;
| | - Alain Lortholary
- GINECO & Confluent Private Hospital, Institut de Cancérologie Catherine de Sienne, 44200 Nantes, France;
| | - Daniel Pissaloux
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, 69000 Lyon, France
| | - Alexandra Leary
- GINECO & Medical Oncology Department, Institut Gustave Roussy, 94805 Villejuif, France;
| | - Jacobus Pfisterer
- AGO & Zentrum für Gynäkologische Onkologie, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany;
| | - Alexandre Eeckhoutte
- INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.m) PSL Research University, Institut Curie, 75005 Paris, France;
| | - Felix Hilpert
- AGO & Krankenhaus Jerusalem, Moorkamp 2-6, Onkologische Tagesklinik, 20357 Hamburg, Germany;
| | - Michel Fabbro
- GINECO & ICM Val d’Aurelle, oncologie médicale, 208, Avenue des Apothicaires, 34298 Montpellier, France;
| | - Christophe Caux
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Laboratory for Immunotherapy of Cancer of Lyon (LICL), Centre Léon Bérard, 69000 Lyon, France
| | - Jérôme Alexandre
- GINECO & Medical Oncology Department, Hopital Cochin, 75014 Paris, France;
| | - Aurélie Houlier
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, 69000 Lyon, France
| | - Jalid Sehouli
- AGO & Charité, Medical University of Berlin, Department of Gynecology with Center of Oncological Surgery, Augustenburger Platz 1, 13353 Berlin, Germany;
| | - Emilie Sohier
- Synergie Lyon Cancer, Bio-Informatics Platform, 69000 Lyon, France;
| | - Rainer Kimmig
- AGO & West-German Cancer Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen Germany, 45136 Essen, Germany;
| | - Bertrand Dubois
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Laboratory for Immunotherapy of Cancer of Lyon (LICL), Centre Léon Bérard, 69000 Lyon, France
| | - Dominique Spaeth
- GINECO & Medical Oncology Department Centre d’Oncologie de Gentilly, 54000 Nancy, France;
| | - Isabelle Treilleux
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
| | - Jean-Sébastien Frenel
- GINECO & Medical Oncology Department Institut de cancerologie de l’Ouest site René Gauducheau, 44800 Saint Herblain, France;
| | - Uwe Herwig
- AGO & Albertinen-Krankenhaus, Department Gynecology, Süntelstraße 11a, 22457 Hamburg, Germany;
| | - Olivia Le Saux
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- GINECO & Medical Oncology Department, Centre Léon Bérard, 28, rue Laennec, Université Claude Bernard Lyon 1, 69008 Lyon, France;
| | - Nathalie Bendriss-Vermare
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Laboratory for Immunotherapy of Cancer of Lyon (LICL), Centre Léon Bérard, 69000 Lyon, France
- Correspondence: (J.-D.F.); (N.B.-V.)
| | - Andreas du Bois
- AGO & Evangelische Kliniken Essen Mitte (KEM), 45136 Essen, Germany;
| |
Collapse
|
3
|
Zeng XY, Yuan J, Wang C, Zeng D, Yong JH, Jiang XY, Lan H, Xiao SS. circCELSR1 facilitates ovarian cancer proliferation and metastasis by sponging miR-598 to activate BRD4 signals. Mol Med 2020; 26:70. [PMID: 32640974 PMCID: PMC7346459 DOI: 10.1186/s10020-020-00194-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 06/22/2020] [Indexed: 02/08/2023] Open
Abstract
Background Ovarian cancer is one of the most common gynecologic cancers and has high mortality rate due to the lack of early diagnosis method and efficient therapeutic agents. circCELSR1 is up-regulated in ovarian cancer, but its role and mechanisms in ovarian cancer are unclear. Methods Gene expression of circCELSR1, miR-598 and BRD4 in ovarian cells was examined by qRT-PCR. Protein level was determined by Western blotting. Bioinformatic analysis and luciferase assay determined the molecular binding among circCELSR1, miR-598 and BRD4 3′ UTR. Cell proliferation, migration, invasion and apoptosis were determined by colony formation, wound healing assay, transwell assay and flow cytometry analysis, respectively. An abdominal cavity metastasis nude mice model was used to determine the in vivo function of circCELSR1. Results circCELSR1 and BRD4 were promoted, but miR-598 was suppressed in various ovarian cancer cells. circCELSR1 bound to miR-598 and promoted expression of its downstream target BRD4. Knockdown of circCELSR1 suppressed proliferation, migration, invasion and epithelial-mesenchymal transition (EMT), but promoted apoptosis in ovarian cancer cells, and these effects were reversed by miR-598 inhibition or BRD4 overexpression. circCELSR1 inhibition decreased the expression of BRD4 and its downstream proliferation/migration related genes by targeting miR-598. Furthermore, knockdown of circCELSR1 suppressed ovarian cancer growth and metastasis in nude mice. Conclusion Knockdown of circCELSR1 inhibited BRD4-mediated proliferation/migration related signaling via sponging miR-598, thereby repressing ovarian cancer progression. This study provides a new regulatory mechanism of ovarian cancer may facilitate the development of therapeutic agents for ovarian cancer.
Collapse
Affiliation(s)
- Xiang-Yang Zeng
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Jing Yuan
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Chen Wang
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Da Zeng
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Jia-Hui Yong
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Xiao-Yan Jiang
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Hua Lan
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China
| | - Song-Shu Xiao
- Department of Gynecology, the Third Xiangya Hospital of Central South University, No.138 Tongzipo Road, Changsha, 410013, Hunan Province, PR China.
| |
Collapse
|
4
|
Eugène J, Jouand N, Ducoin K, Dansette D, Oger R, Deleine C, Leveque E, Meurette G, Podevin J, Matysiak T, Bennouna J, Bezieau S, Volteau C, Thomas WEA, Chetritt J, Kerdraon O, Fourquier P, Thibaudeau E, Dumont F, Mosnier JF, Toquet C, Jarry A, Gervois N, Bossard C. The inhibitory receptor CD94/NKG2A on CD8 + tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression. Mod Pathol 2020; 33:468-482. [PMID: 31409873 DOI: 10.1038/s41379-019-0322-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 06/13/2019] [Accepted: 06/14/2019] [Indexed: 01/28/2023]
Abstract
We previously demonstrated that HLA-E/β2m overexpression by tumor cells in colorectal cancers is associated with an unfavorable prognosis. However, the expression of its specific receptor CD94/NKG2 by intraepithelial tumor-infiltrating lymphocytes, their exact phenotype and function, as well as the relation with the molecular status of colorectal cancer and prognosis remain unknown. Based on a retrospective cohort of 234 colorectal cancer patients, we assessed the expression of HLA-E, β2m, CD94, CD8, and NKp46 by immunohistochemistry on tissue microarray. The expression profile of HLA-E/β2m on tumor cells and the density of tumor-infiltrating lymphocytes were correlated to the clinicopathological and molecular features (Microsatellite status, BRAF and RAS mutations). Then, from the primary tumors of 27 prospective colorectal cancers, we characterized by multiparameter flow cytometry the nature (T and/or NK cells) and the co-expression of the inhibitory NKG2A or activating NKG2C chain of ex vivo isolated CD94+ tumor-infiltrating lymphocytes. Their biological function was determined using an in vitro redirected cytolytic activity assay. Our results showed that HLA-E/β2m was preferentially overexpressed in microsatellite instable tumors compared with microsatellite stable ones (45% vs. 19%, respectively, p = 0.0001), irrespective of the RAS or BRAF mutational status. However, HLA-E/β2m+ colorectal cancers were significantly enriched in CD94+ intraepithelial tumor-infiltrating lymphocytes in microsatellite instable as well as in microsatellite stable tumors. Those CD94+ tumor-infiltrating lymphocytes mostly corresponded to CD8+ αβ T cells, and to a lesser extent to NK cells, and mainly co-expressed a functional inhibitory NKG2A chain. Finally, a high number of CD94+ intraepithelial tumor-infiltrating lymphocytes in close contact with tumor cells was independently associated with a worse overall survival. In conclusion, these findings strongly suggest that HLA-E/β2m-CD94/NKG2A represents a new druggable inhibitory immune checkpoint, preferentially expressed in microsatellite instable tumors, but also in a subgroup of microsatellite stable tumors, leading to a new opportunity in colorectal cancer immunotherapies.
Collapse
Affiliation(s)
- Juliette Eugène
- Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
| | - Nicolas Jouand
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Kathleen Ducoin
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Delphine Dansette
- Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
| | - Romain Oger
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Cécile Deleine
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Edouard Leveque
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Guillaume Meurette
- Institut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Juliette Podevin
- Institut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
| | - Tamara Matysiak
- Institut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Jaafar Bennouna
- Institut des Maladies de l'Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Stéphane Bezieau
- Université de Nantes, Faculté de Médecine, Nantes, France
- Service de Génétique Médicale, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
| | | | | | | | - Olivier Kerdraon
- Département de Biologie des Cancers, Institut de Cancérologie de l'Ouest, Nantes, France
| | - Pierre Fourquier
- Service de Chirurgie Viscérale et Digestive, Hôpital privé du Confluent, Nantes, France
| | - Emilie Thibaudeau
- Service d'Oncologie Chirurgicale, Institut de Cancérologie de l'Ouest, Nantes, France
| | - Frédéric Dumont
- Service d'Oncologie Chirurgicale, Institut de Cancérologie de l'Ouest, Nantes, France
| | - Jean-François Mosnier
- Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Claire Toquet
- Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Anne Jarry
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Nadine Gervois
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Céline Bossard
- Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France.
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
- LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.
- Université de Nantes, Faculté de Médecine, Nantes, France.
| |
Collapse
|
5
|
Abstract
The recent successes of chimeric antigen receptor T cells in the treatment of hematological malignancies have clearly led to an explosion in the field of adoptive cell therapy for cancer. Current efforts are focused on the translation of this exciting technology to the treatment of solid tumors and the development of allogeneic ‘off-the-shelf’ therapies. γδ T cells are currently gaining considerable attention in this field as their unique biology and established role in cancer immunosurveillance place them in a unique position to potentially overcome these challenges in adoptive cell therapy. Here, we review the relevant aspects of the function of γδ T cells in cancer immunity, and summarize clinical observations and clinical trial results that highlight their emerging role as a platform for the development of safe and effective cancer immunotherapies. γδ T cells are a unique subset of T cells combining innate and adaptive features. Tissue-resident γδ T cells have important functions in tissue and cancer immunosurveillance. γδ T cells are being exploited increasingly for cancer immunotherapy.
Collapse
|
6
|
Zhang Y, Yu S, Han Y, Wang Y, Sun Y. Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment. Oncol Lett 2017; 15:699-709. [PMID: 29399142 PMCID: PMC5772757 DOI: 10.3892/ol.2017.7407] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 06/02/2017] [Indexed: 12/11/2022] Open
Abstract
Human leukocyte antigen-G (HLA-G) is a non-classical HLA molecule, predominantly expressed in cytotrophoblast cells to protect the fetus during pregnancy. Notably, a high frequency of HLA-G expression has been observed in a wide variety of cancer types in previous studies. Furthermore, HLA-G expression in cancer has been considered to be detrimental, since it can protect cancer cells from natural killer cell cytotoxic T lymphocyte-mediated destruction, promote tumor spreading and shorten the survival time of patients by facilitating tumor immune evasion. In addition, HLA-G polymorphisms have been investigated in numerous types of cancer and are considered as risk factors and predictive markers of cancer. This review focuses on HLA-G expression and its polymorphisms in cancer, analyzing the mechanisms of HLA-G in promoting cancer development, and evaluating the potential and value of its clinical application as a diagnostic and prognostic biomarker, or even as a prospective therapeutic target in certain types of tumors.
Collapse
Affiliation(s)
- Yanwen Zhang
- Department of Oncology, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.,Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
| | - Shuwen Yu
- Department of Pharmacy, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
| | - Yali Han
- Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
| | - Yunshan Wang
- Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
| | - Yuping Sun
- Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
| |
Collapse
|
7
|
Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN. Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs 2016; 8:1437-1455. [PMID: 27494775 PMCID: PMC5098446 DOI: 10.1080/19420862.2016.1219005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Antibody therapeutics against different target antigens are widely used in the treatment of different malignancies including ovarian carcinomas, but this disease still requires more effective agents. Improved understanding of the biological features, signaling pathways, and immunological escape mechanisms involved in ovarian cancer has emerged in the past few years. These advances, including an appreciation of the cross-talk between cancer cells and the patient's immune system, have led to the identification of new targets. In turn, potential antibody treatments with various mechanisms of action, including immune activation or toxin-delivery, that are directed at these targets have been developed. Here, we identify established as well as novel targets for antibodies in ovarian cancer, and discuss how they may provide fresh opportunities to identify interventions with enhanced therapeutic potential.
Collapse
Affiliation(s)
- Heather J Bax
- a St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London & NIHR Biomedical Research Center at Guy's and St. Thomas' Hospital and King's College London, Guy's Hospital, King's College London , London , UK.,b Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital , London , UK
| | - Debra H Josephs
- a St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London & NIHR Biomedical Research Center at Guy's and St. Thomas' Hospital and King's College London, Guy's Hospital, King's College London , London , UK.,b Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital , London , UK
| | - Giulia Pellizzari
- a St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London & NIHR Biomedical Research Center at Guy's and St. Thomas' Hospital and King's College London, Guy's Hospital, King's College London , London , UK.,b Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital , London , UK
| | - James F Spicer
- b Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital , London , UK
| | - Ana Montes
- c Department of Medical Oncology , Guy's and St Thomas' NHS Foundation Trust , London , UK
| | - Sophia N Karagiannis
- a St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London & NIHR Biomedical Research Center at Guy's and St. Thomas' Hospital and King's College London, Guy's Hospital, King's College London , London , UK
| |
Collapse
|
8
|
Sasaki T, Kanaseki T, Shionoya Y, Tokita S, Miyamoto S, Saka E, Kochin V, Takasawa A, Hirohashi Y, Tamura Y, Miyazaki A, Torigoe T, Hiratsuka H, Sato N. Microenvironmental stresses induce HLA-E/Qa-1 surface expression and thereby reduce CD8(+) T-cell recognition of stressed cells. Eur J Immunol 2016; 46:929-40. [PMID: 26711740 DOI: 10.1002/eji.201545835] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Revised: 11/29/2015] [Accepted: 12/23/2015] [Indexed: 02/04/2023]
Abstract
Hypoxia and glucose deprivation are often observed in the microenvironment surrounding solid tumors in vivo. However, how they interfere with MHC class I antigen processing and CD8(+) T-cell responses remains unclear. In this study, we analyzed the production of antigenic peptides presented by classical MHC class I in mice, and showed that it is quantitatively decreased in the cells exposed to either hypoxia or glucose deprivation. In addition, we unexpectedly found increased surface expression of HLA-E in human and Qa-1 in mouse tumor cells exposed to combined oxygen and glucose deprivation. The induced Qa-1 on the stressed tumor model interacted with an inhibitory NKG2/CD94 receptor on activated CD8(+) T cells and attenuated their specific response to the antigen. Our results thus suggest that microenvironmental stresses modulate not only classical but also nonclassical MHC class I presentation, and confer the stressed cells the capability to escape from the CD8(+) T-cell recognition.
Collapse
Affiliation(s)
- Takanori Sasaki
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
| | | | - Yosuke Shionoya
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
- Department of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan
| | - Serina Tokita
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Sho Miyamoto
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
| | - Eri Saka
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Vitaly Kochin
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Akira Takasawa
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | | | - Yasuaki Tamura
- Department of Molecular Therapeutics, Center for Food and Medical Innovation, Hokkaido University, Sapporo, Japan
| | - Akihiro Miyazaki
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
| | | | | | - Noriyuki Sato
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| |
Collapse
|
9
|
Chromatin states modify network motifs contributing to cell-specific functions. Sci Rep 2015; 5:11938. [PMID: 26169043 PMCID: PMC4500950 DOI: 10.1038/srep11938] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Accepted: 06/11/2015] [Indexed: 01/06/2023] Open
Abstract
Epigenetic modification can affect many important biological processes, such as cell proliferation and apoptosis. It can alter chromatin conformation and contribute to gene regulation. To investigate how chromatin states associated with network motifs, we assembled chromatin state-modified regulatory networks by combining 269 ChIP-seq data and chromatin states in four cell types. We found that many chromatin states were significantly associated with network motifs, especially for feedforward loops (FFLs). These distinct chromatin state compositions contribute to different expression levels and translational control of targets in FFLs. Strikingly, the chromatin state-modified FFLs were highly cell-specific and, to a large extent, determined cell-selective functions, such as the embryonic stem cell-specific bivalent modification-related FFL with an important role in poising developmentally important genes for expression. Besides, comparisons of chromatin state-modified FFLs between cancerous/stem and primary cell lines revealed specific type of chromatin state alterations that may act together with motif structural changes cooperatively contribute to cell-to-cell functional differences. Combination of these alterations could be helpful in prioritizing candidate genes. Together, this work highlights that a dynamic epigenetic dimension can help network motifs to control cell-specific functions.
Collapse
|
10
|
Zheng H, Lu R, Xie S, Wen X, Wang H, Gao X, Guo L. Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer. Cancer Sci 2015; 106:522-8. [PMID: 25711417 PMCID: PMC4452152 DOI: 10.1111/cas.12641] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2014] [Revised: 02/11/2015] [Accepted: 02/13/2015] [Indexed: 01/12/2023] Open
Abstract
Human leukocyte antigen-E (HLA-E) is one of the most extensively studied non-classical MHC class I molecules that is almost non-polymorphic. Only two alleles (HLA-E*0101 and HLA-E*0103) are found in worldwide populations, and suggested to be functional differences between these variants. The HLA-E molecule can contribute to the escape of cancer cells from host immune surveillance. However, it is still unknown whether HLA-E gene polymorphisms might play a role in cancer immune escape. To explore the association between HLA-E alleles and the susceptibility to serous ovarian cancer (SOC), 85 primary SOC patients and 100 healthy women were enrolled. Here, we indicated that high frequency of HLA-E*0103 allele existed in SOC patients by the allele-specific quantitative real-time PCR method. The levels of HLA-E protein expression in SOC patients with the HLA-E*0103 allele were higher than those with the HLA-E*0101 allele using immunohistochemistry analysis. The cell surface expression and functional differences between the two alleles were verified by K562 cells transfected with HLA-E*0101 or HLA-E*0103 allelic heavy chains. The HLA-E*0103 allele made the transfer of the HLA-E molecule to the cell surface easier, and HLA-E/peptides complex more stable. These differences ultimately influenced the function of natural killer cells, showing that the cells transfected with HLA-E*0103 allele inhibited natural killer cells to lysis. This study reveals a novel mechanism regarding the susceptibility to SOC, which is correlated with the HLA-E*0103 allele.
Collapse
Affiliation(s)
- Hui Zheng
- Department of Clinical Laboratory, Shanghai Cancer Center, Fudan UniversityShanghai, China
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| | - Renquan Lu
- Department of Clinical Laboratory, Shanghai Cancer Center, Fudan UniversityShanghai, China
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| | - Suhong Xie
- Department of Clinical Laboratory, Shanghai Cancer Center, Fudan UniversityShanghai, China
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| | - Xuemei Wen
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| | - Hongling Wang
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| | - Xiang Gao
- Department of Clinical Laboratory, Shanghai Cancer Center, Fudan UniversityShanghai, China
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| | - Lin Guo
- Department of Clinical Laboratory, Shanghai Cancer Center, Fudan UniversityShanghai, China
- Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China
| |
Collapse
|
11
|
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 2013; 19:5564-71. [PMID: 23897901 DOI: 10.1158/1078-0432.ccr-12-3697] [Citation(s) in RCA: 90] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Human leukocyte antigen G (HLA-G) is a nonclassical MHC class I molecule that exerts important tolerogenic functions. Its main physiologic expression occurs in the placenta, where it participates in the maternal tolerance toward the fetus. HLA-G expression was found in embryonic tissues, in adult immune privileged organs, and in cells of the hematopoietic lineage. It is expressed in various types of primary solid (melanoma, head and neck, lung, urogenital, gastrointestinal, and breast cancers) and hematologic malignancies (acute leukemia, lymphomas) and metastases. HLA-G ectopic expression is observed in cancer, suggesting that its expression is one strategy used by tumor cells to escape immune surveillance. In this review, we will focus on HLA-G expression in cancers and its association with the prognosis. We will highlight the underlying molecular mechanisms of impaired HLA-G expression, the immune tolerant function of HLA-G in tumors, and the potential diagnostic use of membrane-bound and soluble HLA-G as a biomarker to identify tumors and to monitor disease stage. As HLA-G is a potent immunoinhibitory molecule, its blockade remains an attractive therapeutic strategy against cancer. Elimination of HLA-G-expressing cancer cells would be important in the efficacy of anticancer therapies.
Collapse
Affiliation(s)
- Giuseppe Curigliano
- Authors' Affiliation: Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milan, Italy
| | | | | | | |
Collapse
|